MGMT and glioblastoma: This study was designed to evaluate the association of clinical outcome (progression-free survival, PFS2, and OS) and molecular characteristics (MGMT status) with radiomic features from tumoral and peritumoral tissue on gadolinium-enhanced T1-weighted MR images in glioblastoma patients at first progression.